Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.
To verify product quality, the amount of residual DNA in a drug’s final dosage form must meet guidelines established by multiple regulatory agencies. Each regulatory agency has specific guidelines for acceptable limits depending on the product and therapeutic modality.
In this webinar, we’ll discuss the challenges, risks, and considerations involved in developing and using In-house developed residual testing solutions, and the benefits of using commercial kits for residual DNA testing, including shorter process development time, simplified regulatory acceptance, and helping to enable focus on process-specific development tasks.
Join this webinar to learn more about: